Women with germline inactivating mutations in the BRCA1 and BRCA2 genes are at significantly elevated risk of breast and ovarian cancer. Clinical genetic testing for mutations in these genes has become an important part of clinical practice because of the surgical prevention and targeted treatment benefits associated with knowledge of the presence of a cancer predisposing mutation. However, this process is often complicated by the detection of Variants of Uncertain Significance (VUS), which are predominantly missense mutations with an unknown influence on protein function and unknown association with cancer risk. The lack of information about these VUS means that individuals found to carry these variants cannot benefit from enhanced risk assessment or make informed decisions about surgical prevention or tailored treatment options such as platinum and PARP inhibitor therapy. Here we propose to determine the cancer relevance of VUS found throughout the BRCA1 and BRCA2 genes by developing a comprehensive model incorporating new genetic and functional approaches for VUS classification. However, because BRCA1 and BRCA2 are large proteins, with several established distinct functions that may or may not have a role in cancer development, the contribution of the different functions to tumor suppression and cancer risk must be determined before assays can be applied to VUS classification. Thus, in Aim1 we will perform a comprehensive functional analysis of BRCA1 variants to determine which molecular functions contribute to tumor suppression and in Aim 2 we will perform a comprehensive functional analysis of BRCA2 variants to determine which molecular functions influence the risk of cancer. Specifically, we will evaluate the influence of known pathogenic and non- pathogenic variants on defined functions of BRCA1 and BRCA2 and then extend our analyses to VUS using the assays found to be associated with cancer risk.
In Aim 3 we propose to extend the multifactorial model for classification of BRCA1 and BRCA2 VUS. Here we will develop new methods allowing incorporation of personal and family histories of VUS probands into an established predictive model. We will apply the model to classification of candidate moderate risk VUS, and most importantly, we will develop a Bayesian mixture model that integrates quantitative functional assay data with genetic data for the purposes of VUS classification.
These efforts will result in determination of which of the known functions of BRCA1 and BRCA2 are associated with cancer risk and will lead to development of functional assays for characterization of VUS. It will then be possible to combine these assays with results from genetic studies to formally classify the cancer relevance of many VUS in the BRCA1 and BRCA2 genes. Overall, the study will ensure improved selection of VUS carriers who can benefit from various forms of intervention to prevent and/or treat breast cancer.
|Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620|
|Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574|
|Lilyquist, Jenna; Ruddy, Kathryn J; Vachon, Celine M et al. (2018) Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. Cancer Epidemiol Biomarkers Prev 27:380-394|
|Guidugli, Lucia; Shimelis, Hermela; Masica, David L et al. (2018) Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 102:233-248|
|Hart, Steven N; Hoskin, Tanya; Shimelis, Hermela et al. (2018) Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genet Med :|
|Welsh, Jessemae L; Hoskin, Tanya L; Day, Courtney N et al. (2017) Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. Ann Surg Oncol 24:3067-3072|
|Barrdahl, Myrto; Rudolph, Anja; Hopper, John L et al. (2017) Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. Int J Cancer 141:1830-1840|
|Kuchenbaecker, Karoline B; McGuffog, Lesley; Barrowdale, Daniel et al. (2017) Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 109:|
|Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438|
|Hamdi, Yosr; Soucy, Penny; Kuchenbaeker, Karoline B et al. (2017) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161:117-134|
Showing the most recent 10 out of 105 publications